not directly comparable due to different patient criteria (severe and critical) But still very interesting to what others are doing:
https://investor.regeneron.com/news...nd-sanofi-provide-update-us-phase-23-adaptive
- Forums
- ASX - By Stock
- Regeneron Covid trial
not directly comparable due to different patient criteria...
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.09 |
Change
-0.015(1.36%) |
Mkt cap ! $1.261B |
Open | High | Low | Value | Volume |
$1.10 | $1.10 | $1.09 | $71.10K | 64.94K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 22736 | $1.09 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.10 | 22700 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4001 | 1.160 |
1 | 605 | 1.155 |
1 | 1000 | 1.110 |
3 | 13907 | 1.105 |
3 | 12360 | 1.100 |
Price($) | Vol. | No. |
---|---|---|
0.995 | 52 | 1 |
1.050 | 127 | 1 |
1.060 | 11262 | 1 |
1.070 | 6250 | 2 |
1.080 | 3166 | 5 |
Last trade - 10.06am 12/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |